Introduction
============

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of cancer-related death.[@b1-clep-4-033] Tumor stage is a key determinant of CRC prognosis and provides guidance to the optimal planning of treatment. Furthermore, the stage is important for monitoring trends in CRC incidence and mortality across populations. The tumor, node, metastasis (TNM) stage classification is based on the anatomic extent of the tumor, including the tumor size (T), the number of lymph nodes involved (N), and the presence of metastases (M).[@b2-clep-4-033]

Since 1943, all incident cancers in Denmark have been recorded in the Danish Cancer Registry (DCR).[@b3-clep-4-033],[@b4-clep-4-033] Reporting to the DCR has been mandatory since 1987, and ascertainment of cancer cases in the registry is virtually complete.[@b3-clep-4-033]--[@b5-clep-4-033] TNM staging has been recorded for cancer cases since 2004.[@b4-clep-4-033] However, no studies have hitherto examined the completeness of TNM staging in the DCR. Some studies have suggested that factors such as age, race, sex, marital status, income, and residence influence the proportion of unstaged cancers.[@b6-clep-4-033]--[@b8-clep-4-033] Given that information on TNM might not be missing at random, unstaged CRCs could bias results of studies monitoring cancer incidence and outcomes. We therefore aimed to evaluate the completeness of CRC staging in the DCR according to the TNM classification -- overall, and by sex, age, year of diagnosis, and level of comorbidity.

Methods
=======

We performed this study in Denmark, within a population of 5.4 million inhabitants. The Danish National Health Service provides free medical care by general practitioners and hospitals. All health-related services are registered with a unique ten-digit personal identifier -- the CPR number -- assigned since 1968 to each resident.[@b9-clep-4-033] This number allows unambiguous individual-level data linkage between Danish registers.

Ascertaining patients with CRC
------------------------------

We used the DCR to identify patients with a primary diagnosis of CRC between January 1, 2004 and December 31, 2009. During this period, the DCR recorded cancer diagnoses according to the International Classification of Disease, 10th revision (ICD-10).[@b3-clep-4-033],[@b4-clep-4-033] Colon and rectal cancer cases were identified by the ICD-10 codes C18 and C19--20, respectively. From the DCR, we also obtained information on CPR number, date of diagnosis, age, sex, and TNM stage at diagnosis.

Comorbidity data
----------------

The Danish National Patient Register contains data on all nonpsychiatric discharges from hospitals in Denmark since 1977 and all outpatient visits since 1995.[@b10-clep-4-033] Information includes CPR number, date of contact/discharge, and diagnoses according to ICD-10 since 1994. From the Danish National Patient Register, we obtained information on preexisting comorbidity 10 years prior to the date of CRC diagnosis using a modified version of the Charlson Comorbidity Index (CCI). The CCI is based on disease categories that are each weighted according to the adjusted risk of one-year mortality.[@b11-clep-4-033],[@b12-clep-4-033] Excluding CRC from the index, we defined the level of comorbidity as low (CCI score = 0), medium (CCI score = 1--2), and high (CCI score ≥ 3).

Statistical analysis
--------------------

We calculated the completeness of TNM stage registration and the corresponding 95% confidence intervals (CIs), both overall and for each component individually (ie, T, N, and M). The completeness was defined as the number of individuals with no missing factors (ie, T1--4, N0--3, and M0--1) divided by the total number of patients. We stratified completeness by sex, age (0--39 years, 40--59 years, 60--79 years, and ≥ 80 years), year of colon or rectal cancer diagnosis, and CCI score.

Complete information on T, N, and M is necessary to derive a definite TNM stage in the DCR. For additional categorization of colon or rectal cancers into localized, regional, distant, or unknown stages, we designed an algorithm, allowing certain missing stage components, under the assumption that the remaining information was sufficient to provide a meaningful categorization (eg, cancers assigned T4, Nx, M1 in the DCR were categorized as "distant"; see [Appendix 1](#t4-clep-4-033){ref-type="table"}). The algorithm was based on knowledge of tumor growth and clinical coding practice In addition, we restricted the analysis to histologic verified CRC cases.

Analyses were performed using SAS (v 9.2; SAS Institute, Inc, Cary, NC).

Results
=======

Colon cancer
------------

A total of 15,976 patients were diagnosed with colon cancer during the 2004--2009 period ([Table 1](#t1-clep-4-033){ref-type="table"}). Females accounted for 51.5% of the colon cancer cases, with a median age at diagnosis of 74 years. The median age for men was 72 years. Overall TNM completeness was 67.8% (95% CI: 67.0%--68.5%) ([Table 1](#t1-clep-4-033){ref-type="table"}). Examining each stage component, the overall registration proportion was slightly higher for M (83.5% \[95% CI: 82.9%--84.0%\]) than for T (80.3% \[95% CI: 79.7%--80.9%\]) and N (76.4% \[95% CI: 75.8%--77.1%\]) ([Table 2](#t2-clep-4-033){ref-type="table"}). We found that 93.3% of the colon cancer cases were histologically verified. Restricting to this proportion, overall TNM was 70.8% (95% CI: 70.1%--71.5%). Differences in TNM completeness between the sexes were minor, with males exhibiting a slightly higher completeness than females. Completeness of the TNM staging decreased with (1) increasing age, from 68.5% (95% CI: 61.2%--75.1%) in patients \<40 years to 57.0% (95% CI: 55.5%--58.5%) in patients ≥ 80 years; (2) year of diagnosis, from 71.3% (95% CI: 69.5%--73.0%) in 2004 to 64.8% (95% CI: 63.0%--66.6%) in 2009; and (3) level of comorbidity, from 70.8% (95% CI: 69.9%--71.7%) in patients with lowest comorbidity (CCI score = 0) to 57.2% (95% CI: 54.8%--59.5%) among those with high level of comorbidity (CCI score ≥ 3) ([Table 1](#t1-clep-4-033){ref-type="table"}). Using the algorithm for stage classification ([Appendix 1](#t4-clep-4-033){ref-type="table"}), we found that 5473 (34.3%) of the colon cancers were localized, whereas regional and distant cases accounted for 3463 (21.7%) and 4022 (25.2%), respectively. A total of 3018 (18.9%) colon cancers were not classifiable according to the algorithm (data not shown).

Rectal cancer
-------------

Of the 8,292 rectal cancer patients diagnosed during the study period ([Table 1](#t1-clep-4-033){ref-type="table"}), 40.3% were female with a median age at diagnosis of 71 years. Median age for men was 69 years. Overall, TNM was complete for 68.1% (95% CI: 67.0%--69.1%) of the rectal cancer cases. M was the most complete stage component (84.8% \[95% CI: 84.0%--85.6%\]), T completeness was close to that of M (84.0% \[95% CI: 83.2%--84.8%\]), but N completeness was considerably lower (72.9% \[95% CI: 72.0%--73.9%\]) ([Table 3](#t3-clep-4-033){ref-type="table"}). Restricting to the 95.3% of the rectum cancer cases that were histologically verified left the overall TNM completeness nearly unchanged (69.6% \[95% CI: 70.8%--71.5%\]). TNM completeness was slightly higher in males compared with females and decreased with increasing age, from 78.3% (95% CI: 68.6%--86.1%) in patients \<40 years to 49.2% (95% CI: 46.8%--51.6%) in patients ≥ 80 years. Also, TNM completeness declined with comorbidity level, from 71.4% (95% CI: 70.2%--72.6%) in patients with lowest comorbidity to 52.0% (95% CI: 48.2%--55.9%) in patients with a high comorbidity level. TNM completeness did not vary by year of diagnosis ([Table 1](#t1-clep-4-033){ref-type="table"}). According to our stage algorithm, 2569 (31.0%) rectal cancers were localized, 2350 (28.3%) were regional, and 1633 (19.7%) were distant. For a total of 1740 (21.0%) rectal cancer cases, the TNM stage could not be assessed based on the available information (data not shown).

Discussion
==========

To our knowledge, this nationwide population-based study is the first to evaluate the completeness of TNM registration of CRC in the DCR. Although the ascertaining of cancer diagnoses in the DCR is virtually complete,[@b3-clep-4-033]--[@b5-clep-4-033] we found that approximately one-third of CRC patients had missing data on TNM classification. In particular, completeness declined with increasing age and level of comorbidity. Using a clinically based stage algorithm, we showed that the proportion of staged cases rose markedly.

The completeness of CRC staging in the US Surveillance, Epidemiology, and End Results, or SEER, database appears to be higher than what we observed in the DCR. Worthington et al reported that only 5.1% of colon and 7.8% of rectal cancers were unstaged during the 1991--2002 period.[@b8-clep-4-033] However, the SEER summary stage is computed using an algorithm that allows staging with one or two missing stage components. Although we also designed a stage algorithm that allowed some missing stage information, it might differ from the SEER template. Thus, the completenesses of TNM staging in the US and Danish registers is probably not directly comparable.

We found that TNM completeness varied substantially by age and level of comorbidity, which is in accordance with previous US studies.[@b6-clep-4-033]--[@b8-clep-4-033],[@b13-clep-4-033],[@b14-clep-4-033] In a study examining the proportion of unstaged disease at 18 cancer sites, Merill et al reported a steep increase with age.[@b6-clep-4-033] Likewise, marital status, race, sex, and prognosis of the cancers influenced staging. Koroukian et al reported that patients with more comprehensive needs for care (as measured by dependence of home health care and nursing home care) were two to five times as likely to be unstaged, compared with patients with fewer needs.[@b13-clep-4-033]

TNM completeness for colon cancer in the DCR decreased slightly during the study period, whereas rectal cancer staging remained stable over time. In contrast, a number of studies have reported a decrease in the proportion of patients with unstaged CRCs over recent years.[@b6-clep-4-033]--[@b8-clep-4-033] In 2004, the DCR computerized and automated the registration of incident cancer cases, facilitating fast notifications from clinicians. A potential negative consequence is that the cancer cases might be reported before the clinical workup has been finalized. However, considering the number of initiatives aiming to improve cancer control, including the implementation of Danish National Cancer Plans in 2000 and 2005,[@b15-clep-4-033],[@b16-clep-4-033] and the establishment of a comprehensive CRC database by the Danish Colorectal Cancer Group in 2001,^19^ one would have expected improvements in the registration of TNM stage over the study period.

A main strength of this study is its population-based design within the setting of a uniform tax-supported health care system, largely eliminating selection bias. Our study population was identified from updated nationwide registers. Although coding errors on CRC diagnoses and comorbidities cannot be ruled out, data from the DCR and the Danish National Patient Register have been found very complete and highly valid.[@b3-clep-4-033],[@b5-clep-4-033],[@b12-clep-4-033]

Our study also had limitations. The completeness and accuracy of CRC diagnoses in the automated version of DCR (from 2004 on) have not been specifically validated. Moreover, we had no information on the underlying reasons for the missing information on TNM stages in the DCR, although plausible explanations include incomplete reporting and genuine difficulties on the part of the clinician or pathologist in determining the stage of the particular cancer case. For example, patients who initially received oncological therapy might not have been registered with complete details on TNM. We found that the most vulnerable patients were least likely to undergo staging, suggesting cessation of diagnostic procedures, including lymph node status, if fragility did not allow further treatment. We also observed that approximately 6% of CRC diagnoses were not histologically verified. However, although it might be expected that the majority of non-histologically verified cases pertained to patients with high comorbidity, restriction of the study population to histologically verified CRC cases yielded results quite similar to those presented.

The DCR is a valuable source for cancer research and statistics. Despite the high level of completeness of the diagnoses in this registry, we found that one-third of CRC patients had missing TNM-stage information, although the proportion of unstaged cases declined markedly with our use of a clinically based stage algorithm. However, completeness varied differentially with age and level of comorbidity, indicating that TNM data are not missing at random. This finding warrants serious consideration of the methodological implications in future epidemiological studies on cancer incidence and survival.
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###### 

Algorithm for colorectal cancer (CRC) staging according to the TNM classification

  Tumor stage                                          TNM[a](#tfn11-clep-4-033){ref-type="table-fn"}
  ---------------------------------------------------- ------------------------------------------------
  Localized                                            T1--4,x N0 M0
                                                       T1--2 N0 Mx
                                                       T1 Nx M0,x
  Regional                                             T1--4,x N1--2 M0
  Distant                                              T1--4,x N0--2,x M1
  Unknown[b](#tfn12-clep-4-033){ref-type="table-fn"}   T2--4,x Nx M0,x
                                                       T3--4,x N0 Mx
                                                       T1--4,x N1--2 Mx

**Notes:**

In all, 466 CRC cases were assigned N3 (categorized as N2 in the algorithm);

Thirty CRC cases were assigned T0, Ta, or Tis (categorized as unknown stage in the algorithm).

**Abbreviation:** TNM, tumor, node, metastasis.

###### 

TNM completeness for colon and rectal cancer; overall and by sex, age, year, and comorbidity

                                                              Colon Cancer   Rectal cancer                                              
  ----------------------------------------------------------- -------------- --------------- ------ -------------- ------ ------ ------ --------------
  **Overall**                                                 15,976         10,824          67.8   (67.0--68.5)   8292   5643   68.1   (67.0--69.1)
  **Sex**                                                                                                                               
  Female                                                      8233           5534            67.2   (66.2--68.2)   3341   2180   65.3   (63.6--66.9)
  Male                                                        7743           5290            68.3   (67.3--69.4)   4951   3463   70.0   (68.7--71.2)
  **Age**                                                                                                                               
  ≤39 years                                                   168            115             68.5   (61.2--75.1)   63     65     78.3   (68.6--86.1)
  40--59 years                                                2327           1737            74.6   (72.9--76.4)   1667   1266   75.9   (73.9--78.0)
  60--79 years                                                9262           6568            70.9   (70.0--71.8)   4926   3517   71.4   (70.1--72.7)
  ≥ 80 years                                                  4219           2404            57.0   (55.5--58.5)   1616   795    49.2   (46.8--51.6)
  **Year of diagnosis**                                                                                                                 
  2004                                                        2555           1822            71.3   (69.5--73.0)   1339   930    69.5   (67.0--71.9)
  2005                                                        2615           1782            68.1   (66.3--69.9)   1284   858    66.8   (64.2--69.4)
  2006                                                        2704           1885            69.7   (68.0--71.4)   1417   962    67.9   (65.4--70.3)
  2007                                                        2656           1802            67.9   (66.1--69.6)   1371   950    69.3   (66.8--71.7)
  2008                                                        2706           1757            64.9   (63.1--66.7)   1442   938    65.1   (62.6--67.5)
  2009                                                        2740           1776            64.8   (63.0--66.6)   1439   1005   69.8   (67.4--72.2)
  **Comorbidity**[a](#tfn2-clep-4-033){ref-type="table-fn"}                                                                             
  Low                                                         9617           6806            70.8   (69.9--71.7)   5464   3903   71.4   (70.2--72.6)
  Medium                                                      4706           3073            65.3   (63.9--66.7)   2192   1409   64.3   (62.3--66.3)
  High                                                        1653           945             57.2   (54.8--59.5)   636    331    52.0   (48.2--55.9)

**Notes:**

Level of comorbidity according to the Charlson comorbidity index (CCI) score; Low (CCI score = 0), Medium (CCI score = 1--2), High (CCI score ≥ 3).

**Abbreviations:** CI, confidence interval; TNM, tumor, node, metastasis.

###### 

T, N, and M completeness for colon cancer; overall and by sex, age, year, and comorbidity

                                                              Total    T completeness   N completeness   M completeness                                                  
  ----------------------------------------------------------- -------- ---------------- ---------------- ---------------- -------- ------ -------------- -------- ------ --------------
  **Overall**                                                 15,976   12,831           80.3             (79.7--80.9)     12,212   76.4   (75.8--77.1)   13,334   83.5   (82.9--84.0)
  **Sex**                                                                                                                                                                
  Female                                                      8233     6611             80.3             (79.4--81.2)     6257     76.0   (75.1--76.9)   6802     82.6   (81.8--83.4)
  Male                                                        7743     6220             80.3             (79.4--81.2)     5955     76.9   (76.0--77.8)   6532     84.4   (83.5--85.2)
  **Age (in years)**                                                                                                                                                     
  ≤39                                                         168      134              79.8             (73.2--85.3)     128      76.2   (69.3--82.2)   141      83.9   (77.8--88.9)
  40--59                                                      2327     1966             84.5             (83.0--85.9)     1914     82.3   (80.7--83.8)   2081     89.4   (88.1--90.6)
  60--79                                                      9262     7655             82.7             (81.9--83.4)     7324     79.1   (78.2--79.9)   7950     85.8   (85.1--86.5)
  ≥ 80                                                        4219     3076             72.9             (71.6--74.2)     2846     67.5   (66.0--68.9)   3162     75.0   (73.6--76.2)
  **Year of diagnosis**                                                                                                                                                  
  2004                                                        2555     2205             86.3             (84.9--87.6)     2082     81.5   (80.0--83.0)   2141     83.8   (82.3--85.2)
  2005                                                        2615     2191             83.8             (82.3--85.2)     2074     79.3   (77.7--80.8)   2141     81.9   (80.4--83.3)
  2006                                                        2704     2223             82.2             (80.7--83.6)     2132     78.9   (77.3--80.4)   2242     82.9   (81.5--84.3)
  2007                                                        2656     2104             79.2             (77.6--80.7)     2016     75.9   (74.3--77.5)   2225     83.8   (82.3--85.1)
  2008                                                        2706     2048             75.7             (74.0--77.3)     1960     72.4   (70.7--74.1)   2265     83.7   (82.3--85.1)
  2009                                                        2740     2060             75.2             (73.5--76.8)     1948     71.1   (69.4--72.8)   2320     84.7   (83.3--86.0)
  **Comorbidity**[a](#tfn5-clep-4-033){ref-type="table-fn"}                                                                                                              
  Low                                                         9617     7965             82.8             (82.1--83.6)     7589     78.9   (78.1--79.7)   8242     85.7   (85.0--86.4)
  Medium                                                      4706     3690             78.4             (77.2--79.6)     3511     74.6   (73.4--75.8)   3822     81.2   (80.1--82.3)
  High                                                        1653     1176             71.1             (68.9--73.3)     1112     67.3   (65.0--69.5)   1270     76.8   (74.8--78.8)

**Notes:**

Level of comorbidity according to the Charlson comorbidity index (CCI) score; Low (CCI score = 0), Medium (CCI score = 1--2), High (CCI score ≥ 3).

**Abbreviations:** CI, confidence interval; T, tumour; N, node; M, metastasis.

###### 

T, N, and M completeness for rectal cancer; overall and by sex, age, year, and comorbidity

                                                              Total   T completeness   N completeness   M completeness                                              
  ----------------------------------------------------------- ------- ---------------- ---------------- ---------------- ------ ------ -------------- ------ ------ --------------
  **Overall**                                                 8292    6964             84.0             (83.2--84.8)     6048   72.9   (72.0--73.9)   7032   84.8   (84.0--85.6)
  **Sex**                                                                                                                                                           
  Female                                                      3341    2739             82.0             (80.7--83.3)     2354   70.5   (68.9--72.0)   2762   82.7   (81.4--83.9)
  Male                                                        4951    4225             85.3             (84.3--86.3)     3694   74.6   (73.4--75.8)   4270   86.3   (85.3--87.2)
  **Age (in years)**                                                                                                                                                
  ≤39                                                         83      73               88.0             (79.7--93.6)     69     83.1   (74.0--90.0)   76     91.6   (84.2--96.2)
  40--59                                                      1667    1483             89.0             (87.4--90.4)     1338   80.3   (78.3--82.1)   1515   90.9   (89.4--92.2)
  60--79                                                      4926    4285             87.0             (86.0--87.9)     3765   76.4   (75.2--77.6)   4275   86.8   (85.8--87.7)
  ≥ 80                                                        1616    1123             69.5             (67.2--71.7)     876    54.2   (51.8--56.6)   1166   72.2   (69.9--74.3)
  **Year of diagnosis**                                                                                                                                             
  2004                                                        1339    1167             87.2             (85.3--88.9)     998    74.5   (72.2--76.8)   1121   83.7   (81.7--85.6)
  2005                                                        1284    1081             84.2             (82.1--86.1)     926    72.1   (69.6--74.5)   1086   84.6   (82.5--86.5)
  2006                                                        1417    1201             84.8             (82.8--86.6)     1035   73.0   (70.7--75.3)   1221   86.2   (84.3--87.9)
  2007                                                        1371    1158             84.5             (82.5--86.3)     1014   74.0   (71.6--76.2)   1173   85.6   (83.6--87.3)
  2008                                                        1442    1156             80.2             (78.1--82.2)     1007   69.8   (67.4--72.2)   1205   83.6   (81.6--85.4)
  2009                                                        1439    1201             83.5             (81.5--85.3)     1068   74.2   (71.9--76.4)   1226   85.2   (83.3--87.0)
  **Comorbidity**[a](#tfn8-clep-4-033){ref-type="table-fn"}                                                                                                         
  Low                                                         5464    4711             86.2             (85.3--87.1)     4163   76.2   (75.1--77.3)   4749   86.9   (86.0--87.8)
  Medium                                                      2192    1793             81.8             (80.1--83.4)     1512   69.0   (67.0--70.9)   1806   82.4   (80.8--83.9)
  High                                                        636     460              72.3             (68.8--75.7)     373    58.7   (54.8--62.4)   477    75.0   (71.5--78.3)

**Notes:**

Level of comorbidity according to the Charlson comorbidity index score (CCI); Low (CCI score = 0), Medium (CCI score = 1--2), High (CCI score ≥ 3).

**Abbreviations:** CI, confidence interval; T, tumour; N, node; M, metastasis.
